tbuckley/cabot-search huggingface dataset:
Adolescent Hypertension and Risk for Early-Onset Type 2 Diabetes: A Nationwide Study of 1.9 Million Israeli Adolescents
Authors: Boris Fishman, Ehud Grossman, Inbar Zucker, Omri Orr, Miri Lutski, Aya Bardugo, Cole D. Bendor, Yoav Leiba, Tali Cukierman-Yaffe, Estela Derazne, Ofri Mosenzon, Dorit Tzur, Zivan Beer, Orit Pinhas-Hamiel, Tamar Fishman, Arnon Afek, Amir Tirosh, Itamar Raz, Hertzel C. Gerstein, Gilad Twig
Journal: Diabetes Care (2020)

The incidence of adolescent hypertension is growing worldwide, mostly in conjunction with the growing obesity prevalence (1,2). Adolescent hypertension was shown to be a risk factor for cardiovascular and renal outcomes later in life, thus promoting current guidelines to screen all pediatric and adolescent population for hypertension (1,3). Here, we elucidate the association of adolescent hypertension and early-onset type 2 diabetes in a nationwide cohort of adolescents.

In this population-based, retrospective cohort study we linked the Israeli Defense Forces conscription center database with the Israeli National Diabetes Registry (INDR). One year prior to mandatory military service at age 17 years, Israeli adolescents undergo comprehensive medical evaluation based on their medical history, an interview and physical examination that includes measurements of height, weight, and blood pressure. Included were adolescents who were examined between 1 January 1993 and 31 December 2016. Excluded were those with prior diagnosis of dysglycemia and those with missing baseline height or weight data (3.8% in total).

Essential hypertension diagnosis was confirmed by a board-specified nephrologist based on a preexisting diagnosis or screening for hypertension as described previously (1). Briefly, adolescents with blood pressure measurement during the screening assessment of >140/90 mmHg were referred for further investigation. The final diagnosis was made when the average of 10 additional outpatient blood pressure measurements was >140/90 mmHg, when at least 50% of the measurements were above this level, and after exclusion of secondary hypertension. The primary outcome was incident type 2 diabetes as documented by the INDR, which captures all cases of diabetes in Israel with a sensitivity of 95.1% (2).

Cox models were applied. Follow-up started at the day of the first medical examination and ended at the date of diabetes diagnosis, 31 December 2016, or death—whichever came first. Due to the previously described …
Next Generation Genomic Analyses in T-ALL Patients Identify Recurrent and Novel Genomic Abnormalities
Authors: Laura N Eadie, Jacqueline Rehn, Susan L Heatley, Barbara J McClure, Caitlin Schutz Schutz, James Breen, Timothy P. Hughes, David T Yeung, Rosemary Sutton, Deborah L White
Journal: Blood (2020)
Safety and Demonstrated Efficacy of Placenta-Derived Cell Therapy PLX-R18 in Subjects with Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation: A Phase I International Multi-Center Study
Authors: Hillard Lazarus, Carolina Escobar, Leland Metheny, Joseph P. McGuirk, Tsila Zuckerman, Mark Litzow, Scott D. Rowley, Racheli Ofir, Liran Shani, Jacob M. Rowe
Journal: Blood (2020)
Oncologist Sub-Specialization, Care Setting, and Multiple Myeloma Treatment and Outcomes
Authors: Amy J. Davidoff, Jessica B Long, Natalia Neparidze, Jan Philipp Bewersdorf, Rory M. Shallis, Nikolai A. Podoltsev, Rong Wang, Steven D. Gore, Amer M. Zeidan, Scott F. Huntington
Journal: Blood (2020)
Filter Clotting with Continuous Renal Replacement Therapy in COVID-19
Authors: Rachel P. Rosovsky, Paul Endres, Soophia H Zhao, Scott Krinsky, Shananssa G Percy, Omer Kamal, Russel J. Roberts, Natasha Lopez, Meghan E Sise, David J Steele, Andrew L Lundquist, Eugene P Rhee, Kathryn A Hibbert, Charles C Hardin, Finnian R McCausland, Peter G. Czarnecki, Walter P Mutter, Nina E Tolkoff-Rubin, Andrew S Allegretti
Journal: Blood (2020)
Favorable Immune Reconstitution in Patients Administered Anti-Thymocyte Globulin (ATG) Early in the Course of Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation
Authors: Viktoriya Zelikson, Natasha Raman, Anatevka Rebiero, Elizabeth Krieger, Catherine H Roberts, Gary Simmons, Amir Ahmed Toor
Journal: Blood (2020)
Genetic Features of AML with MLL-Rearrangement and NPM1 Mutation: An Interim-Analysis of HM-Screen-Japan 01
Authors: SungGi Chi, Naoko Hosono, Takahiro Yamauchi, Kentaro Fukushima, Hirohiko Shibayama, Seiichiro Katagiri, Akihiko Gotoh, Motohito Okabe, Takanobu Morishita, Masamitsu Yanada, Kazuhito Yamamoto, Naohito Fujishima, Naoto Takahashi, Reiki Ogasawara, Takeshi Kondo, Yoshikazu Utsu, Nobuyuki Aotsuka, Yoshimasa Kamoda, Kensuke Usuki, Kanenari Takemura, Yasuyuki Nagata, Takaaki Ono, Tsutomu Kobayashi, Junya Kuroda, Hiroto Horiguchi, Satoshi Iyama, Suguru Fukuhara, Koji Izutsu, Makoto Nakamura, Kazuto Togitani, Kensuke Kojima, Kaoru Yamamoto, Yukinori Nakamura, Makoto Yoshimitsu, Kenji Ishitsuka, Kenichi Miyamoto, Yosuke Minami
Journal: Blood (2020)
A Phase 1/2 Study of INCB000928 As Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104)
Authors: Stephen T. Oh, Jason Gotlib, Sanjay Mohan, Haris Ali, Ekatherine Asatiani, Francis Seguy, Feng Zhou, Srdan Verstovsek
Journal: Blood (2020)
Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001
Authors: Maria Lia Palomba, Leo I. Gordon, Tanya Siddiqi, Jeremy S. Abramson, Manali Kamdar, Matthew A. Lunning, David G. Maloney, Charalambos Andreadis, Jon E. Arnason, Nilanjan Ghosh, Amitkumar Mehta, Scott R. Solomon, Thalia Farazi, Jacob Garcia, Christine Dehner, Ken Ogasawara, Jie Gao, Michael Wang
Journal: Blood (2020)
Arrhythmia Burden in Patients with Indolent Lymphoma
Authors: Mujtaba Soniwala, Saadia Sherazi, Susan Schleede, Scott McNitt, Tina Faugh, Jeremiah Moore, Justin Foster, Clive S. Zent, Paul M. Barr, Patrick M. Reagan, Jonathan W. Friedberg, Eugene Storozynsky, Ilan Goldenberg, Carla Casulo
Journal: Blood (2020)
Cladribine, Idarubicin, Cytarabine (ara-C), and Venetoclax in Treating Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
Authors: Patrick K Reville, Hagop M. Kantarjian, Gautam Borthakur, Musa Yilmaz, Guillermo Montalban-Bravo, Courtney D. DiNardo, Michael Andreeff, Naval Daver, Nitin Jain, Steven M. Kornblau, Elias Jabbour, Nicholas J. Short, Yesid Alvarado, Maro Ohanian, Prithviraj Bose, Lucia Masarova, Sa A Wang, Rebecca S. S Tidwell, Zeev E. Estrov, Guillermo Garcia-Manero, Marina Konopleva, Farhad Ravandi, Tapan M. Kadia
Journal: Blood (2020)
AB0026 Limphocytis expression of p-glycoprotein on peripheral blood in rheumatoid arthritis patients
Authors: IR Kolosova, ER Polosukhina, AY Baryshnikov, GV Loukina, YA Sigidin
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> <h3>Objectives</h3> To examine the expression of the multidrug resistance P-glycoprotein (P-gp 170) in patients with rheumatoid arthritis (RA). P-gp 170 is a pump molecule which decreases intracellular drug concentrations by increasing drug efflux from cells. <h3>Methods</h3> Peripheral blood samples were obtained from 10 patients with active RA, and 8 normal subjects. The patients were treated with NSAIDs. Previous therapy with DMARDs was ineffective in 7 patients. 3 patients were not treated with DMARDs. Fluorescent flow cytometry on FACScan (Becfon Dichinson) was used to assess the expression of P-gp 170, with monoclonal antibodies (UIC2 PE, Immunotech). <h3>Results</h3> The expression of P-gp on peripheral blood lymphocytes was elevated compared with control (29,6 ± 9,4% vs 1,6 ± 0,4%, P = 0,03). We did not observe any association between glycoprotein P expression and age, sex, disease activity, duration and stage of RA. The expression of P-gp 170 correlated with expression of antigens CD8 (r = 0,85) and CD71 (r = 0,83). <h3>Conclusion</h3> The patient with RA showed increased expression of P-gp 170 as compared to the control. Further studies are needed to evaluate the potential implication of P-gp in drug resistance in RA.
Conversion to Biosimilar Pegfilgrastim-Jmdb from Pegfilgrastim with on-Body Injector Device in Diffuse Large B-Cell Lymphoma: Simulation Modeling of Cost-Savings and Budget-Neutral Expanded Access to Prophylaxis and Anti-Neoplastic Therapy Considering Device Failure Rate
Authors: Ali McBride, Karen MacDonald, Ivo Abraham
Journal: Blood (2020)
Increased Incidence of New-Onset Diabetes Mellitus Type II Following Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide for Sickle Cell Disease
Authors: Dilan A Patel, Josu de la Fuente, Michael Matheney, Leena Karnik, Heidi Chen, Katie S. Gatwood, Kathryn A. Culos, Karina L Wilkerson, Michael T. Byrne, Salyka M. Sengsayadeth, Stacey Ann Goodman, Bhagirathbhai Dholaria, Bipin N. Savani, Wichai Chinratanalab, Reena Jayani, Jim Connelly, Carrie Kitko, Brian G. Engelhardt, Adetola A. Kassim
Journal: Blood (2020)
Eltrombopag in Chronic Myelomonocytic Leukemia (CMML) with Severe Thrombocytopenia: Final Results of a Multicenter Phase II Study
Authors: Florence Rabian, Jérôme Lambert, Daniela Barbieri, Berengere Gruson, Sylvain Thepot, Thorsten Braun, Norbert Vey, Jacques Delaunay, Laurence Legros, Julie Lejeune, Anouk Walter-petrich, Rosa Sapena, Nathalie Droin, Fatiha Chermat, Francoise Porteu, Daniel Lusina, Lionel Ades, Eric Solary, Pierre Fenaux, Raphael Itzykson
Journal: Blood (2020)
Abstract MP101: Functional Maintenance of the Sarcomere Requires Bag3-dependent Autophagy
Authors: Thomas G Martin, Arthur M Feldman, Monte S Willis, Jonathan A Kirk
Journal: Circulation Research (2020)

Bcl2-associated athanogene-3 (BAG3) is a pro-autophagy co-chaperone highly expressed in the heart. Clinical studies show BAG3 haploinsufficiency and mutations are associated with heart failure (HF). However, these studies are largely observational and fail to go beyond the observed phenotype and study mechanism. One study in neonatal myocytes suggests a role for BAG3 in structural maintenance of the sarcomere. However, the structural and functional significance of BAG3 in adult myocytes is not known. We found that myofilament BAG3 expression decreases in human heart failure and is associated with impaired myofilament force-generating capacity (F max ). To assess whether rescuing BAG3 levels could restore function, we used a mouse model of HF and treated with BAG3 gene therapy via AAV9. Myofilament function was assessed in skinned cardiomyocytes by force-calcium relationship. HF mice experienced a reduction in F max , but this was fully restored to sham levels by BAG3 gene therapy.To explore mechanism, we used mass spectrometry to identify the BAG3-interactome at the myofilament and found heat shock proteins (HSP) 70 and B8 among the top hits. Immunofluorescence further showed that HSP70, B8, and BAG3 each localized to the sarcomere z-disk. This BAG3-Hsp complex had previously been described to promote ubiquitin-dependent autophagy in skeletal muscle. Notably, in both human HF samples and in the mouse HF model, myofilament ubiquitin levels increased significantly. However, BAG3 gene therapy in HF reduces ubiquitin levels and restores autophagy flux. This suggests that BAG3 serves a role in proteostasis for the sarcomere, which may explain the functional effect of BAG3 gene therapy.To further explore the impact of the BAG3/HSP complex on myofilament function, we used a mouse model with the P209L BAG3 mutation, which had previously been described to disrupt client processing by the complex. We found cardiomyocytes from P209L mice had significantly reduced F max and elevated myofilament ubiquitin levels, suggesting BAG3-dependent autophagy is required to maintain function. Together, our data identify a functional role for BAG3 at the sarcomere and indicate BAG3-mediated autophagy is an important mechanism for maintaining myofilament proteostasis.
Combination Therapy Approved for Adults With Mesothelioma
Authors: Rebecca Voelker
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Novel Underappreciated Role for the Extracellular Adenosine Triphosphate (ATP)-P2X4 Purinergic Receptor Axis in the Homing and Engraftment of HSPCs
Authors: Mateusz Adamiak, Arjun Thapa, Kamila Bujko, Valentina Pensato, Magdalena Kucia, Janina Ratajczak, Mariusz Z Ratajczak
Journal: Blood (2020)
Abstract 16451: Single Cell RNA-Seq Analysis of Lung Endothelial Heterogeneity Following Inflammatory Injury Identifies Novel Endothelial Cell Subpopulations
Authors: Shang Gao, Lianghui Zhang, Mark Maienschein-Cline, Shiqin Xiong, Yang Dai, Asrar B. Malik, Jalees Rehman
Journal: Circulation (2018)

Introduction: Recent studies have identified cellular heterogeneity at a single cell level using single cell RNA-Seq analysis in various tissue types. However, little is known about the existence o...
Pooled Analysis of Cardiovascular Events from Clinical Trials Evaluating Acalabrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia (CLL)
Authors: Jennifer R Brown, John C. Byrd, Paolo Ghia, Jeff P Sharman, Peter Hillmen, Deborah M. Stephens, Clare Sun, Wojciech Jurczak, John M. Pagel, Alessandra Ferrajoli, Priti Patel, Marshall Baek, Tamara Lezhava, Nataliya Kuptsova-Clarkson, Javid J. Moslehi, Richard R. Furman
Journal: Blood (2020)
Abstract 20386: Controlling Nutritional Status Score is the Most Powerful Prognostic Index in Acute Decompensated Heart Failure Patients: A Prospective Comparative Study With Other Nutritional Indexes and Prealbumin
Authors: Iyo Ikeda, Takahisa Yamada, Takashi Morita, Yoshio Furukawa, Shunsuke Tamaki, Yusuke Iwasaki, Masato Kawasaki, Atsushi Kikuchi, Tsutomu Kawai, Masahiro Seo, Eiji Fukuhara, Jun Nakamura, Makoto Abe, Kiyomi Kayama, Masatsugu Kawahira, Kazuya Tanabe, Masatake Fukunami
Journal: Circulation (2017)

Background: Malnutrition is associated with increased mortality risk in patients with heart failure. The controlling nutritional status score (CONUT), prognostic nutritional index (PNI), and geriat...
Hyperbaric Oxygen Therapy Improve Acute Graft-Versus-Host Disease By Activating the Nrf2/HO-1 Pathway in a Mice Model
Authors: Chao Xue, Qian Zhang, Hao Chen, Dai Yuan, Xin Wang, Xiao Lv, Xueling Ge, Kang Lu, Lingyan Zhang, Yujie Jiang
Journal: Blood (2020)
Enhanced Outcome Prediction in Early Stage Classical Hodgkin Lymphoma Using Pre-Treatment Biomarkers and Interim PET (BioPET); A Sub-Analysis of the UK NCRI RAPID Trial
Authors: Kim M Linton, Joanna M Oladipo, Nicholas Counsell, Janet Taylor, Cathy Burton, Rachel Oakley, Joanna Williams, Sally F Barrington, Richard Byers, Timothy Illidge, John A. Radford
Journal: Blood (2020)
ABO Blood Type and Outcomes in a Diverse COVID-19 Infected Population
Authors: Sonal Paul, Nisha Patel, Chathula Kumarasinghe, Neil Nimkar, Angelica Singh, Nivetha Vishnuvardhan, Farah Ashraf, Anita Mazloom, Rich Kodama, Amardeep Kalsi, Soeb Usta, Abeer Ashfaq, Peter Gregos, Uqba Khan, Jeremy Weingarten, Eshan Patel
Journal: Blood (2020)
Cytomegalovirus Reactivation in Hematopoietic Stem Cell Transplant Recipients in High Endemic Population
Authors: Muhammad Farhan, Qamar Un Nisa Chaudhry, Syed Kamran Mahmood, Tariq Ghafoor, Raheel Iftikhar, Nighat Shahbaz, Mehreen Ali Khan, Tariq Khattak, Ghassan Shamshad, Jahanzeb Rehman, Parvez Ahmed
Journal: Blood (2020)
HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Health-Related Quality of Life (HRQoL) Analysis
Authors: Albert Oriol, Paul G. Richardson, María-Victoria Mateos, Alessandra Larocca, Joan Blade Creixenti, Michele Cavo, Paula Rodríguez-Otero, Maxim Norkin, Omar Nadeem, John W. Hiemenz, Hani Hassoun, Cyrille Touzeau, Adrián Alegre Amor, Agne Paner, Christopher Maisel, Amitabha Mazumder, Anastasios Raptis, Noemí Puig, Peter Strang, Anna Sandberg, Christian Jaques, Marcus Thuresson, Marie Orre, Xavier Leleu
Journal: Blood (2020)
Spermidine improves gut barrier integrity and gut microbiota function in diet-induced obese mice
Authors: Lingyan Ma, Yinhua Ni, Zhe Wang, Wenqing Tu, Liyang Ni, Fen Zhuge, Aqian Zheng, Luting Hu, Yufeng Zhao, Liujie Zheng, Zhengwei Fu
Journal: Gut Microbes (2020)

Obesity is associated with impaired intestinal barrier function and dysbiosis of the gut microbiota. Spermidine, a polyamine that acts as an autophagy inducer, has important benefits in patients with aging-associated diseases and metabolic dysfunction. However, the mechanism of spermidine on obesity remains unclear. Here, we show that spermidine intake is negatively correlated with obesity in both humans and mice. Spermidine supplementation causes a significant loss of weight and improves insulin resistance in diet-induced obese (DIO) mice. These effects are associated with the alleviation of metabolic endotoxemia and enhancement of intestinal barrier function, which might be mediated through autophagy pathway and TLR4-mediated microbial signaling transduction. Moreover, spermidine causes the significant alteration of microbiota composition and function. Microbiota depletion compromises function, while transplantation of spermidine-altered microbiota confers protection against obesity. These changes might partly be driven by an SCFA-producing bacterium, Lachnospiraceae NK4A136 group, which was decreased in obese subjects and subsequently increased by spermidine. Notably, the change of Lachnospiraceae NK4A136 group is significantly correlated with enhanced gut barrier function induced by spermidine. Our results indicate that spermidine supplementation may serve as a viable therapy for obesity.
Abstract 215: Negative Regulation of Adherens Junction Formation Patterns Cellular Parameters Required for Cardiac Pacemaking
Authors: Kandace Thomas, Trevor Henley, Simone Rossi, Michael Bressan
Journal: Circulation Research (2020)

Cardiac Pacemaker Cells (CPCs) rhythmically initiate the electrical impulses that drive heart contractions. Paradoxically, CPCs display the highest rate of spontaneous depolarization in the heart despite being subjected to unfavorable electrochemical conditions that should theoretically suppress their activity. How CPCs overcome such barriers remains a fundamentally unresolved topic in our understanding of cardiac electrophysiology. To address this, we have used computational modeling, high resolution in vivo imaging, and direct genetic manipulation of CPCs to examined the developmental processes that coordinate CPC electrical integration into the embryonic heart. Through these studies we have uncovered a series of previously unrecognized cytoarchitectural patterning events that are critical for CPC function. Specifically, we have identified that CPCs uniquely internalize their adherens junction complexes during early cardiac morphogenesis. As a result, CPCs adopt physical attributes, such as small cell size, and electrical characteristics, including poor gap junctional coupling, that are highly beneficial for maintenance of their excitability. Importantly, our data also demonstrate that ectopic adherens junction formation severely perturbs CPC function in a force dependent manner. Thus, these data highlight that regulation of cell-cell interactions controls the basic structural parameters needed to support CPC activity in the heart and that local cellular mechanics should be a design consideration as cellular-based therapeutics for the correction of CPC dysfunction become increasingly feasible.
Integrative Analysis of the Genomic and Transcriptomic Landscape of Relapsed/Refractory Multiple Myeloma Patients Treated With Venetoclax in Combination With Bortezomib and Dexamethasone: Biomarker Analyses From the Phase 3 BELLINI Study
Authors: Michael E. O'Dwyer, Andrew Spencer, Shaji K. Kumar, Rakesh Popat, Philippe Moreau, Monique Dail, Muhammad Jalaluddin, Xiaoqing Yang, Xin Lu, Zheng Zha, Fengjiao Dunbar, Deeksha Vishwamitra, Christine Mantis, Amal Melhem-Bertrandt, Jeremy A. Ross, Simon J Harrison
Journal: Blood (2020)
Keeping the liver fit with TREM2 during hepatic carcinogenesis
Authors: Francisco Javier Cubero
Journal: Gut (2020)

In humans, two genes on chromosome 6p21 encode the triggering receptors expressed on myeloid cells-1 (TREM1) and triggering receptor expressed on myeloid cells-2 (TREM2), members of the immunoglobulin-lectin-like superfamily.1 Interestingly, the activation of TREM1 and TREM2 results in divergent cellular responses. While TREM1 promotes inflammation, TREM2 exerts anti-inflammatory effects, thus maintaining tissue homeostasis during pathological processes.

The possibility of modulating TREM2 recently caught the eye of researchers and industry for the exploration of its cell-specific biological role in inflammation-derived disorders for future pharmacological development. TREM2 is expressed in immature monocyte-derived dendritic cells (DCs), certain neutrophils and tissue-specific macrophages, including osteoclasts and microglia.2 Indeed, the impact of TREM2 as a sensor of inflammation during tissue injury was analysed and reported in neurogenerative disorders,3 obesity,4 atherosclerosis,5 fatty liver disease2 and tumorigenesis (eg, glioma and gastric cancer).2

Evidence for the function of TREM2 in the liver has been recollected not only from human tissue but also from a wide array of preclinical models of liver injury ranging from acute (toxic) liver injury to advanced chronic liver disease and end-stage hepatocellular carcinoma (HCC).

During acute liver injury, TREM2 functions to dampen hepatic damage via the modulation of the inflammatory response. TREM2-deficient Kupffer cells (KCs) when exposed to lipopolysaccharide displayed induction of inflammatory cytokines (eg, interleukin-6 and tumour necrosis factor). Moreover, experimental toxic liver injury—carbon tetrachloride or acetaminophen overdose—further corroborated the critical role of TREM2 in maintaining liver function by suppressing the monocyte chemoattractant protein-1 (MCP-1)-derived recruitment …
Rituximab with Dose-Adjusted EPOCH (R-DA-EPOCH) with or without Autologous Stem Cell Transplantation (ASCT) As First Line Treatment in Patients with Aggressive B-Cell Lymphoma with <i>MYC</i> and <i>BCL-2</i> and/or <i>BCL-6</i> Gene Rearrangements or Increase Copy Number
Authors: Alessandra Tucci, Alessandro Re, Chiara Pagani, Anna Guidetti, Anna Dodero, Fabrizio Marino, Ivana Casaroli, Giulia Soverini, Rosa Daffini, Monica Balzarotti, Giulia Campostrini, Luisa Lorenzi, Piera Balzarini, Fabio Facchetti, Carmelo Carlo-Stella, Paolo Corradini, Giuseppe Rossi
Journal: Blood (2020)
Poor Treatment Outcomes of Young (&amp;lt;60 Years) African American Patients (Pts) Diagnosed with Acute Myeloid Leukemia (AML) (Alliance)
Authors: Bhavana Bhatnagar, Qiuhong Zhao, James L. Fisher, Jessica Kohlschmidt, Krzysztof Mrózek, Deedra Nicolet, Shelley Orwick, James S. Blachly, Alice S. Mims, Christopher J. Walker, Andrew J Carroll, Bayard L. Powell, Jonathan E. Kolitz, Electra D. Paskett, Clara D. Bloomfield, Richard M. Stone, John C. Byrd, Albert de la Chapelle, Ramiro Garzon, Ann-Kathrin Eisfeld
Journal: Blood (2020)